 |
 |

Pertussis in an Infant Adopted From RussiaMay 2002
JAMA. 2002;288:40.
MMWR. 2002;51:394-395
On May 2, 2002, the North Carolina Department of Health and Human Services
notified CDC about an infant aged 10 months adopted from Russia who had culture-confirmed
pertussis diagnosed. On April 8, the adoptive parents picked him up in the
orphan ward at hospital A in Bryansk and noticed that the child had upper
respiratory congestion and cough. The adoptive parents reported that the infant
had not received any vaccinations and that another infant living in the same
room in hospital A had a severe cough. The adopted infant subsequently was
examined by a local physician, who diagnosed his condition as a "cold," and
the infant was taken to the U.S. Embassy in Moscow, where the parents were
interviewed for an immigrant visa for the child.
On April 24, the infant and his parents traveled from Moscow to Raleigh,
North Carolina, through New York on commercial airline flights. On April 26,
the infant was seen as an outpatient at a local clinic; a culture of a nasopharyngeal
swab confirmed infection with Bordetella pertussis.
The infant improved after treatment with clarithromycin and was administered
the first dose of diphtheria and tetanus toxoids and acellular pertussis vaccine
(DTaP). The parents were placed on azithromycin for prophylaxis.
CDC is collaborating with the U.S. Embassy, adoption agencies, visa
applicant medical clinics in Moscow, and the airline to identify and notify
persons who might have been exposed to the infant during his communicable
period. The airline is working to identify those passengers who might have
been exposed to the infant during his flights to North Carolina. CDC is collaborating
with state health departments, who are notifying and ensuring appropriate
chemoprophylaxis and vaccination for exposed passengers in their jurisdiction.
Health-care providers and public health officials are advised to consider
pertussis when evaluating or notified of a person with an acute illness characterized
by cough with paroxysms, whoop, or post-tussive gagging or vomiting. Following
are CDC guidelines on the management of patients with pertussis and their
contacts:
- For symptomatic patients, test by culture of nasopharyngeal
aspirate or swab; a nasopharyngeal DacronTM swab should be used. Swabs
or aspirate should be placed in Regan Lowe transport media if direct inoculation
of selective media is not possible.
- For hospitalized patients, respiratory isolation
(droplet precautions) is recommended for at least the first 5 days of antimicrobial
treatment.
- For symptomatic patients, the treatment of choice
for pertussis is erythromycin for 14 days. Trimethoprim-sulfamethoxozole is
an alternative antibiotic. Limited clinical data suggest that newer macrolides,
such as azithromycin for 5-7 days or clarithromycin for 14 days, might be
as effective as erythromycin in the treatment of pertussis and are alternatives
for patients who cannot tolerate erythromycin.
- For exposed persons, chemoprophylaxis is recommended
to limit secondary transmission. Exposure is defined as having face-to-face
contact, having direct contact with respiratory, oral, or nasal secretions,
or being in the same room with a coughing pertussis case-patient. The recommended
chemoprophylaxis regimen is erythromycin for 14 days. Alternative therapies
are the same as for symptomatic patients.
- Pertussis vaccination should be initiated or continued
according to the recommended schedule for exposed children aged <7 years
who are undervaccinated or who have received <4 DTaP doses. Exposed children
may receive DTaP dose 2 or 3 if 4 weeks have elapsed after dose 1 or 2, respectively.
Children may receive DTaP dose 4 as early as age 12 months, and preferably
6 months after dose 3. Children should be administered DTaP dose 5 unless
a dose was given within the last 3 years or they are aged
7 years.
Additional information about pertussis is available at http://www.cdc.gov/nip/publications/pertussis/guide.htm.
Reported by:
L Johns, B Rowe-West, J MacCormack, MD, Div of Public Health, North
Carolina Dept of Health and Human Svcs. D Kim, MD, K Murray-Lillibridge, DVM,
S Maloney, MD, J Barrow, M Cetron, MD, Div of Global Migration and Quarantine,
National Center for Infectious Diseases; K Bisgard, DVM, T Tiwari, MD, Epidemiology
and Surveillance Div, National Immunization Program; J Shah, MD, C Ohuabunwo,
MBBS, EIS Officers, CDC.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|